Document 0732
 DOCN  M9490732
 TI    Strong immunogenicity of a multicomponent peptide vaccine developed with
       the branched lysine oligopeptide method for human immunodeficiency virus
       infection.
 DT    9411
 AU    Okuda K; Kaneko T; Yamakawa T; Tanaka S; Shigematsu T; Yamamoto A;
       Hamajima K; Nakajima K; Kawamoto S; Phanuphak P; Department of
       Bacteriology, Yokohama City University School of; Medicine, Fukuura,
       Japan.
 SO    J Mol Recognit. 1993 Sep;6(3):101-9. Unique Identifier : AIDSLINE
       MED/94338751
 AB    We synthesized one V3 peptide each from HTLV-IIIB, Thai A and Thai B,
       conjugating them to the T cell epitope of the env region, and we also
       synthesized a p17 protein peptide of the gag region (HGP-30). These
       peptides were then coupled to 8-lysine copolymers using N-succinimidyl
       maleimido carboxylate (M(r) = ca 60,000). We designated this the
       branched lysine oligopeptide method. The large peptide complexes
       constructed from these four macromolecular peptides were used with
       aluminium hydroxide or complete Freund's adjuvant to immunize mice and
       rabbits four times. ELISA assay showed high titres of anti-peptide
       antibodies to each V3 loop peptide and the HGP-30 peptide. Strong
       inhibition of CD4+ dependent cell fusion was obtained with these
       antisera when IIIB, Thai A and Thai B strains of the human
       immunodeficiency virus (HIV) were used. Strong anti-fusion inhibition
       was also observed with two other HIV strains. In addition, an increase
       of the anti-HIV effect was observed when we used sera obtained by
       multicomponent vaccine immunization. The same kind of inhibition was
       also observed in p24 assay systems using these immunized antisera.
       Activation of IL-2 production in lymphocytes was observed in mice
       immunized with this vaccine. These results suggest that immunization
       with macromolecular peptide complexes can result in strong
       immunogenicity towards HIV-1.
 DE    Amino Acid Sequence  Animal  AIDS Vaccines/*IMMUNOLOGY/ISOLATION & PURIF
       Cell Fusion  Comparative Study  Gene Products, env/GENETICS/IMMUNOLOGY
       Gene Products, gag/GENETICS/IMMUNOLOGY  Human  HIV
       Antibodies/BIOSYNTHESIS  HIV Core Protein p24/BIOSYNTHESIS  HIV Envelope
       Protein gp120/GENETICS/IMMUNOLOGY  HIV-1/GENETICS/*IMMUNOLOGY
       Immunization  Interleukin-2/BIOSYNTHESIS  Lymphocytes/IMMUNOLOGY  Mice
       Mice, Inbred BALB C  Molecular Sequence Data  Peptide
       Fragments/GENETICS/IMMUNOLOGY  Peptides/GENETICS/IMMUNOLOGY  Rabbits
       Support, Non-U.S. Gov't  Vaccines, Synthetic/IMMUNOLOGY/ISOLATION &
       PURIF  JOURNAL ARTICLE

       SOURCE: National Library of Medicine.  NOTICE: This material may be
       protected by Copyright Law (Title 17, U.S.Code).